PlainRecalls
FDA Drug Low Class III Terminated

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61

Reported: February 26, 2020 Initiated: December 13, 2019 #D-0844-2020

Product Description

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61

Reason for Recall

Failed Dissolution Specifications: High out of specification result observed at stability studies.

Details

Recalling Firm
The Harvard Drug Group
Units Affected
246 Cartons
Distribution
U.S.A. Nationwide
Location
Livonia, MI

Frequently Asked Questions

What product was recalled?
Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61. Recalled by The Harvard Drug Group. Units affected: 246 Cartons.
Why was this product recalled?
Failed Dissolution Specifications: High out of specification result observed at stability studies.
Which agency issued this recall?
This recall was issued by the FDA Drug on February 26, 2020. Severity: Low. Recall number: D-0844-2020.